The UCSF Immunoprofiler is comprised of an interdisciplinary group of clinical, academic, and pharmaceutical groups, who are organized to bridge the gap between basic and translational science. The consortium was originally founded by a collaboration between the laboratories of Max Krummel, Adil Daud, and Michael Rosenblum at UCSF. Now organized as a larger consortium of clinical, academic, and pharmaceutical laboratories, each Consortium Member is mining data for value through a common portal. By sharing sample data and information, the Consortium makes best use of limited patient material and aligns the interest of a collection of groups who all seek the next generation of cures for cancer. Presently, there are four Consortium Members that make up the UCSF Immunoprofiler: UCSF, Bristol-Myers Squibb, Amgen, AbbVie, and Pfizer.